Hypersomnia in Children
Conditions
Keywords
hypersomnia, narcolepsy, amylase, salivary sampling
Brief summary
Hypersomnia is defined as a reduced ability to remain awake during the day. There are basically two types of central hypersomnia: narcolepsy and idiopathic hypersomnia. Currently, the diagnosis of these sleep disorders is based on polysomnographic recordings which is difficult to access. Tests of sleepiness (Epworth, Karolinska) are subjective. A biological marker of sleepiness, easily accessible and measurable, would be very useful for the diagnosis and therapeutic follow up of excessive diurnal sleepiness. Salivary secretions appear as good physiological markers. Studies have shown for healthy subjects, that the expression and activity of salivary amylase are increased when subjects are deprived of sleep. The investigators propose to explore the usefulness of salivary biomarkers (including amylase) as a new non-invasive and simple technique for the assessment of excessive daytime sleepiness.
Interventions
PROCEDUREsaliva collection
collection of saliva
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
Subjects with hypersomnia (narcolepsy or idiopathic): * Children and adolescents with hypersomnia (according to ICSD diagnostic criteria 2); narcolepsy or idiopathic hypersomnia (with or without lengthening of sleep), * aged \> 6 years and \<18 years, * no treatment, * Parent consent Control subjects: * healthy children and adolescents without any known pathology, * aged \> 6 years and \<18 years, * matched on sex and age\> 6 years - \<12 years,\> 12 - \<18 years) * Parent Consent
Exclusion criteria
* Subjects with hypersomnia (narcolepsy or idiopathic): * Secondary narcolepsy, * Symptomatic hypersomnia, * Restless legs syndrome, * Sleep apnea syndrome, * Severe neurological, psychiatric, cognitive or endocrinological concomitant disease. Control subjects: * Hypersomnia, * Restless legs syndrome, * Sleep apnea syndrome, * Severe neurological, psychiatric, cognitive or endocrinological concomitant disease, * Sleep disorder evaluated by a score \> 70 on the Sleep Disturbance Scale for Children19, * Excessive daytime sleepiness according to Epworth scales (score \> 10), * Abnormal sleep time according to the age (sleep diary).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determination of the expression and enzymatic activity of salivary amylase. | 3 days | Show an increase of salivary amylase for children with hypersomnia or narcolepsy compared to a group of children matched on age and sex. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of the mean sleep onset latency using the Multiple Sleep Latency Test (MSLT) | 3 days | To highlight a correlation between the degree of somnolence measured by MSLT and the rate of salivary amylase. |
| Measurement of the somnolence using Epworth and Karolinska scales | 3 days | To highlight a correlation between the degree of somnolence measured by the scales and the rate of salivary amylase. |
Countries
France
Outcome results
None listed